The Latest Breaking News from US Food and Drug Administration

Following the U.S. Food and Drug Administration’s ruling in August 2022, nonprescription over-the-counter hearing aids went on sale at pharmacies, supermarkets and consumer electronic stores on Oct. 17, 2022. These devices are intended only for people with perceived mild to moderate hearing loss.

Though the U.S. economy bounced back after shrinking in the first half of the year, falling consumer spending and the rate hikes to tame high inflation might lead the economy into a recession. Hence, investors looking for passive income could invest in fundamentally sound dividend-paying stocks Pfizer (PFE), Sanofi (SNY),…

Nearly half of US infant formula contain corn sugars. Mounting evidence suggests it may not be the best for babies

Uganda health authorities have declared an outbreak of Ebola disease. Ebola outbreaks emerge periodically in several African countries, most notably in the Democratic Republic of Congo (DRC). Public health expert Yap Boum, who has been involved in managing Ebola outbreaks in the past, answers some key questions about Ebola’s history,…

In an Minnesota lab, clear containers hold pig kidneys and livers that scientists hope will someday be transplantable in humans.

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Pre-open movers U.S. stock futures traded higher in early pre-market trade on Wednesday after recording sharp losses on Tuesday following the release of inflation data for August. All the three major indices settled sharply lower, notching their biggest single-session percentage declines since June 2020.

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…